Monica Andreoli
Arvinas (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Advanced Breast Cancer Therapies, Histone Deacetylase Inhibitors Research, Amino Acid Enzymes and Metabolism, Nitric Oxide and Endothelin Effects
Most-Cited Works
- → Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models(2024)132 cited
- → Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer(2019)131 cited
- → Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer(2021)107 cited
- → Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury(2013)85 cited
- → Osteocalcin Production in Primary Osteoblast Cultures Derived from Normal and Hyp Mice(1998)61 cited
- → Synthesis of quaternary α-amino acid-based arginase inhibitors via the Ugi reaction(2013)40 cited
- → A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity(2019)39 cited
- → 2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors(2013)31 cited
- → Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer(2018)3 cited
- → Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader(2023)3 cited